IL6 and endometrial cancer: Higher levels of aldehyde dehydrogenase (ALDH), a characteristic feature of endometrial cancer progenitor and stem cells, upregulates IL-6 and signal transducer CD126 and GP130 expression, while the blockade of the IL6 receptor dramatically suppresses downstream effector IL6/JAK1/STAT3 signaling, eventually reducing tumor cell growth [44].